Transthyretin-Europe Market Status and Trend Report 2013-2023
Report Summary
Transthyretin-Europe Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Transthyretin industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole Europe and Regional Market Size of Transthyretin 2013-2017, and development forecast 2018-2023
Main market players of Transthyretin in Europe, with company and product introduction, position in the Transthyretin market
Market status and development trend of Transthyretin by types and applications
Cost and profit status of Transthyretin, and marketing status
Market growth drivers and challenges
The report segments the Europe Transthyretin market as:
Europe Transthyretin Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
Germany
United Kingdom
France
Italy
Spain
Benelux
Russia
Europe Transthyretin Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
AG-10
ALN-TTRsc02
CRX-1008
EDE-1307
Inotersen Sodium
Others
Europe Transthyretin Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Familial Amyloid Neuropathies
Alzheimer's Disease
Cardomyopathy
Neuropathy
Others
Europe Transthyretin Market: Players Segment Analysis (Company and Product introduction, Transthyretin Sales Volume, Revenue, Price and Gross Margin):
Alnylam Pharmaceuticals Inc
Arcturus Therapeutics Inc
Ionis Pharmaceuticals Inc
Neurimmune Holding AG
Pfizer Inc
Prothena Corp Plc
Regeneron Pharmaceuticals Inc
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
Transthyretin-Europe Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Transthyretin industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole Europe and Regional Market Size of Transthyretin 2013-2017, and development forecast 2018-2023
Main market players of Transthyretin in Europe, with company and product introduction, position in the Transthyretin market
Market status and development trend of Transthyretin by types and applications
Cost and profit status of Transthyretin, and marketing status
Market growth drivers and challenges
The report segments the Europe Transthyretin market as:
Europe Transthyretin Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
Germany
United Kingdom
France
Italy
Spain
Benelux
Russia
Europe Transthyretin Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
AG-10
ALN-TTRsc02
CRX-1008
EDE-1307
Inotersen Sodium
Others
Europe Transthyretin Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Familial Amyloid Neuropathies
Alzheimer's Disease
Cardomyopathy
Neuropathy
Others
Europe Transthyretin Market: Players Segment Analysis (Company and Product introduction, Transthyretin Sales Volume, Revenue, Price and Gross Margin):
Alnylam Pharmaceuticals Inc
Arcturus Therapeutics Inc
Ionis Pharmaceuticals Inc
Neurimmune Holding AG
Pfizer Inc
Prothena Corp Plc
Regeneron Pharmaceuticals Inc
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF TRANSTHYRETIN
1.1 Definition of Transthyretin in This Report
1.2 Commercial Types of Transthyretin
1.2.1 AG-10
1.2.2 ALN-TTRsc02
1.2.3 CRX-1008
1.2.4 EDE-1307
1.2.5 Inotersen Sodium
1.2.6 Others
1.3 Downstream Application of Transthyretin
1.3.1 Familial Amyloid Neuropathies
1.3.2 Alzheimer's Disease
1.3.3 Cardomyopathy
1.3.4 Neuropathy
1.3.5 Others
1.4 Development History of Transthyretin
1.5 Market Status and Trend of Transthyretin 2013-2023
1.5.1 Europe Transthyretin Market Status and Trend 2013-2023
1.5.2 Regional Transthyretin Market Status and Trend 2013-2023
CHAPTER 2 EUROPE MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of Transthyretin in Europe 2013-2017
2.2 Consumption Market of Transthyretin in Europe by Regions
2.2.1 Consumption Volume of Transthyretin in Europe by Regions
2.2.2 Revenue of Transthyretin in Europe by Regions
2.3 Market Analysis of Transthyretin in Europe by Regions
2.3.1 Market Analysis of Transthyretin in Germany 2013-2017
2.3.2 Market Analysis of Transthyretin in United Kingdom 2013-2017
2.3.3 Market Analysis of Transthyretin in France 2013-2017
2.3.4 Market Analysis of Transthyretin in Italy 2013-2017
2.3.5 Market Analysis of Transthyretin in Spain 2013-2017
2.3.6 Market Analysis of Transthyretin in Benelux 2013-2017
2.3.7 Market Analysis of Transthyretin in Russia 2013-2017
2.4 Market Development Forecast of Transthyretin in Europe 2018-2023
2.4.1 Market Development Forecast of Transthyretin in Europe 2018-2023
2.4.2 Market Development Forecast of Transthyretin by Regions 2018-2023
CHAPTER 3 EUROPE MARKET STATUS AND FORECAST BY TYPES
3.1 Whole Europe Market Status by Types
3.1.1 Consumption Volume of Transthyretin in Europe by Types
3.1.2 Revenue of Transthyretin in Europe by Types
3.2 Europe Market Status by Types in Major Countries
3.2.1 Market Status by Types in Germany
3.2.2 Market Status by Types in United Kingdom
3.2.3 Market Status by Types in France
3.2.4 Market Status by Types in Italy
3.2.5 Market Status by Types in Spain
3.2.6 Market Status by Types in Benelux
3.2.7 Market Status by Types in Russia
3.3 Market Forecast of Transthyretin in Europe by Types
CHAPTER 4 EUROPE MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Transthyretin in Europe by Downstream Industry
4.2 Demand Volume of Transthyretin by Downstream Industry in Major Countries
4.2.1 Demand Volume of Transthyretin by Downstream Industry in Germany
4.2.2 Demand Volume of Transthyretin by Downstream Industry in United Kingdom
4.2.3 Demand Volume of Transthyretin by Downstream Industry in France
4.2.4 Demand Volume of Transthyretin by Downstream Industry in Italy
4.2.5 Demand Volume of Transthyretin by Downstream Industry in Spain
4.2.6 Demand Volume of Transthyretin by Downstream Industry in Benelux
4.2.7 Demand Volume of Transthyretin by Downstream Industry in Russia
4.3 Market Forecast of Transthyretin in Europe by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF TRANSTHYRETIN
5.1 Europe Economy Situation and Trend Overview
5.2 Transthyretin Downstream Industry Situation and Trend Overview
CHAPTER 6 TRANSTHYRETIN MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EUROPE
6.1 Sales Volume of Transthyretin in Europe by Major Players
6.2 Revenue of Transthyretin in Europe by Major Players
6.3 Basic Information of Transthyretin by Major Players
6.3.1 Headquarters Location and Established Time of Transthyretin Major Players
6.3.2 Employees and Revenue Level of Transthyretin Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 TRANSTHYRETIN MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 Alnylam Pharmaceuticals Inc
7.1.1 Company profile
7.1.2 Representative Transthyretin Product
7.1.3 Transthyretin Sales, Revenue, Price and Gross Margin of Alnylam Pharmaceuticals Inc
7.2 Arcturus Therapeutics Inc
7.2.1 Company profile
7.2.2 Representative Transthyretin Product
7.2.3 Transthyretin Sales, Revenue, Price and Gross Margin of Arcturus Therapeutics Inc
7.3 Ionis Pharmaceuticals Inc
7.3.1 Company profile
7.3.2 Representative Transthyretin Product
7.3.3 Transthyretin Sales, Revenue, Price and Gross Margin of Ionis Pharmaceuticals Inc
7.4 Neurimmune Holding AG
7.4.1 Company profile
7.4.2 Representative Transthyretin Product
7.4.3 Transthyretin Sales, Revenue, Price and Gross Margin of Neurimmune Holding AG
7.5 Pfizer Inc
7.5.1 Company profile
7.5.2 Representative Transthyretin Product
7.5.3 Transthyretin Sales, Revenue, Price and Gross Margin of Pfizer Inc
7.6 Prothena Corp Plc
7.6.1 Company profile
7.6.2 Representative Transthyretin Product
7.6.3 Transthyretin Sales, Revenue, Price and Gross Margin of Prothena Corp Plc
7.7 Regeneron Pharmaceuticals Inc
7.7.1 Company profile
7.7.2 Representative Transthyretin Product
7.7.3 Transthyretin Sales, Revenue, Price and Gross Margin of Regeneron Pharmaceuticals Inc
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF TRANSTHYRETIN
8.1 Industry Chain of Transthyretin
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF TRANSTHYRETIN
9.1 Cost Structure Analysis of Transthyretin
9.2 Raw Materials Cost Analysis of Transthyretin
9.3 Labor Cost Analysis of Transthyretin
9.4 Manufacturing Expenses Analysis of Transthyretin
CHAPTER 10 MARKETING STATUS ANALYSIS OF TRANSTHYRETIN
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
1.1 Definition of Transthyretin in This Report
1.2 Commercial Types of Transthyretin
1.2.1 AG-10
1.2.2 ALN-TTRsc02
1.2.3 CRX-1008
1.2.4 EDE-1307
1.2.5 Inotersen Sodium
1.2.6 Others
1.3 Downstream Application of Transthyretin
1.3.1 Familial Amyloid Neuropathies
1.3.2 Alzheimer's Disease
1.3.3 Cardomyopathy
1.3.4 Neuropathy
1.3.5 Others
1.4 Development History of Transthyretin
1.5 Market Status and Trend of Transthyretin 2013-2023
1.5.1 Europe Transthyretin Market Status and Trend 2013-2023
1.5.2 Regional Transthyretin Market Status and Trend 2013-2023
CHAPTER 2 EUROPE MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of Transthyretin in Europe 2013-2017
2.2 Consumption Market of Transthyretin in Europe by Regions
2.2.1 Consumption Volume of Transthyretin in Europe by Regions
2.2.2 Revenue of Transthyretin in Europe by Regions
2.3 Market Analysis of Transthyretin in Europe by Regions
2.3.1 Market Analysis of Transthyretin in Germany 2013-2017
2.3.2 Market Analysis of Transthyretin in United Kingdom 2013-2017
2.3.3 Market Analysis of Transthyretin in France 2013-2017
2.3.4 Market Analysis of Transthyretin in Italy 2013-2017
2.3.5 Market Analysis of Transthyretin in Spain 2013-2017
2.3.6 Market Analysis of Transthyretin in Benelux 2013-2017
2.3.7 Market Analysis of Transthyretin in Russia 2013-2017
2.4 Market Development Forecast of Transthyretin in Europe 2018-2023
2.4.1 Market Development Forecast of Transthyretin in Europe 2018-2023
2.4.2 Market Development Forecast of Transthyretin by Regions 2018-2023
CHAPTER 3 EUROPE MARKET STATUS AND FORECAST BY TYPES
3.1 Whole Europe Market Status by Types
3.1.1 Consumption Volume of Transthyretin in Europe by Types
3.1.2 Revenue of Transthyretin in Europe by Types
3.2 Europe Market Status by Types in Major Countries
3.2.1 Market Status by Types in Germany
3.2.2 Market Status by Types in United Kingdom
3.2.3 Market Status by Types in France
3.2.4 Market Status by Types in Italy
3.2.5 Market Status by Types in Spain
3.2.6 Market Status by Types in Benelux
3.2.7 Market Status by Types in Russia
3.3 Market Forecast of Transthyretin in Europe by Types
CHAPTER 4 EUROPE MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Transthyretin in Europe by Downstream Industry
4.2 Demand Volume of Transthyretin by Downstream Industry in Major Countries
4.2.1 Demand Volume of Transthyretin by Downstream Industry in Germany
4.2.2 Demand Volume of Transthyretin by Downstream Industry in United Kingdom
4.2.3 Demand Volume of Transthyretin by Downstream Industry in France
4.2.4 Demand Volume of Transthyretin by Downstream Industry in Italy
4.2.5 Demand Volume of Transthyretin by Downstream Industry in Spain
4.2.6 Demand Volume of Transthyretin by Downstream Industry in Benelux
4.2.7 Demand Volume of Transthyretin by Downstream Industry in Russia
4.3 Market Forecast of Transthyretin in Europe by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF TRANSTHYRETIN
5.1 Europe Economy Situation and Trend Overview
5.2 Transthyretin Downstream Industry Situation and Trend Overview
CHAPTER 6 TRANSTHYRETIN MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EUROPE
6.1 Sales Volume of Transthyretin in Europe by Major Players
6.2 Revenue of Transthyretin in Europe by Major Players
6.3 Basic Information of Transthyretin by Major Players
6.3.1 Headquarters Location and Established Time of Transthyretin Major Players
6.3.2 Employees and Revenue Level of Transthyretin Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 TRANSTHYRETIN MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 Alnylam Pharmaceuticals Inc
7.1.1 Company profile
7.1.2 Representative Transthyretin Product
7.1.3 Transthyretin Sales, Revenue, Price and Gross Margin of Alnylam Pharmaceuticals Inc
7.2 Arcturus Therapeutics Inc
7.2.1 Company profile
7.2.2 Representative Transthyretin Product
7.2.3 Transthyretin Sales, Revenue, Price and Gross Margin of Arcturus Therapeutics Inc
7.3 Ionis Pharmaceuticals Inc
7.3.1 Company profile
7.3.2 Representative Transthyretin Product
7.3.3 Transthyretin Sales, Revenue, Price and Gross Margin of Ionis Pharmaceuticals Inc
7.4 Neurimmune Holding AG
7.4.1 Company profile
7.4.2 Representative Transthyretin Product
7.4.3 Transthyretin Sales, Revenue, Price and Gross Margin of Neurimmune Holding AG
7.5 Pfizer Inc
7.5.1 Company profile
7.5.2 Representative Transthyretin Product
7.5.3 Transthyretin Sales, Revenue, Price and Gross Margin of Pfizer Inc
7.6 Prothena Corp Plc
7.6.1 Company profile
7.6.2 Representative Transthyretin Product
7.6.3 Transthyretin Sales, Revenue, Price and Gross Margin of Prothena Corp Plc
7.7 Regeneron Pharmaceuticals Inc
7.7.1 Company profile
7.7.2 Representative Transthyretin Product
7.7.3 Transthyretin Sales, Revenue, Price and Gross Margin of Regeneron Pharmaceuticals Inc
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF TRANSTHYRETIN
8.1 Industry Chain of Transthyretin
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF TRANSTHYRETIN
9.1 Cost Structure Analysis of Transthyretin
9.2 Raw Materials Cost Analysis of Transthyretin
9.3 Labor Cost Analysis of Transthyretin
9.4 Manufacturing Expenses Analysis of Transthyretin
CHAPTER 10 MARKETING STATUS ANALYSIS OF TRANSTHYRETIN
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
